XNCRNasdaqPharmaceutical PreparationsFiscal year ends December 31
Xencor Inc
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$23.19+0.34 (+1.49%)
Close on Oct 19, 2026
- Market cap
- $1.76B
- P/E (TTM)
- –
- Dividend yield
- –
Xencor Inc revenue by segment
By business segment
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Royalties | $80.28M | $67.49M | $55.80M | $152.10M | $80.30M | $17.80M | $5.00M | – | – | – | 63.9% | +18.9% |
| Milestone | $45.30M | $34.50M | $88.50M | $5.50M | $21.00M | $50.20M | $23.20M | $20.50M | $26.00M | $5.00M | 36.1% | +31.3% |
| License | $0 | $8.50M | $0 | $0 | $80.80M | $50.20M | $112.20M | – | $100.00K | $69.80M | 0.0% | -100.0% |
| Collaboration | $0 | $0 | $30.32M | $7.00M | $93.00M | $4.50M | $16.30M | $20.10M | $20.10M | $34.20M | 0.0% | – |
| Non-Cash Royalty | – | – | $14.60M | $0 | $0 | – | – | – | – | – | – | – |
| Non-cash royalties | – | $66.90M | $14.60M | $0 | – | – | – | – | – | – | – | – |
By region
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | – | – | – | – | – | $64.10M | $142.70M | $40.60M | $30.20M | – | – | – |
| Non - United States | – | – | – | – | – | $58.60M | $14.00M | – | $16.00M | – | – | – |
From the segment and revenue-disaggregation notes of Xencor's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.